Former Chief Financial Officer · Arbutus Biopharma Corp (ABUS)

David Hastings

FY2025 is the first fiscal year CompBrief holds for David Hastings as a named executive officer of Arbutus Biopharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,218,362

Compensation figures as of the proxy filed April 14, 2026 (DEF 14A).

David Hastings compensation by year

Arbutus Biopharma Summary Compensation Table · the one fiscal year held
In US dollars, as Arbutus Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$138,613
Bonus$0
Stock awards$296,429
Option awards$944,268
Non-equity incentive$0
Pension and deferred compensation$0
All other$839,052
Total$2,218,362

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 14, 2026, accession 0001140361-26-014623, and prior-year filings. Open the filing on EDGAR.

Arbutus Biopharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Michael McElhaughFormer Interim President and Chief Executive Officer$3,578,150
Tuan NguyenChief Financial Officer$2,416,995
David Hastings · this pageFormer Chief Financial Officer$2,218,362
Lindsay AndroskiPresident and Chief Executive Officer$1,369,013

The full Arbutus Biopharma compensation record

free company brief

This page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arbutus Biopharma's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy